Anti-FLT4 Antibody
Cat: 10806-T16
Cat: 10806-T16
Price:
Size:
Number:
Anti-FLT4 Antibody (Rabbit Polyclonal antibody) General Information
Product name
Anti-FLT4 Antibody
Validated applications
ELISA
Species reactivity
Reacts with: Human
Specificity
Human FLT4
Immunogen
Recombinant Human VEGFR3 / FLT-4 protein (Catalog#10806-H08H)
Preparation
Produced in rabbits immunized with purified, recombinant Human VEGFR3 / FLT-4 (rh VEGFR3 / FLT-4 ; Catalog#10806-H08H; NP_002011.2; Met1-Ile776). VEGFR3 / FLT-4 specific IgG was purified by Human VEGFR3 / FLT-4 affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Anti-FLT4 Antibody (Rabbit Polyclonal antibody) Validated Applications
| Application | Dilution |
|---|---|
| ELISA | 1:5000-1:10000 |
Please Note: Optimal concentrations/dilutions should be determined by the end user.
Anti-FLT4 Antibody: Alternative Names
Anti-FLT-4 Antibody; Anti-FLT-41 Antibody; Anti-FLT41 Antibody; Anti-LMPH1A Antibody; Anti-PCL Antibody; Anti-VEGF Receptor 3 Antibody; Anti-VEGFR-3 Antibody; Anti-VEGFR3 Antibody
FLT4 Background Information
Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.
Full Name
fms related tyrosine kinase 4
Research Areas
- Cardiovascular>>Angiogenesis>>Angiogenesis Growth Factor & Receptor
- Cardiovascular>>Vasculature>>Endothelium>>Endothelial Cell Markers
- Cardiovascular>>Vasculature>>Endothelium>>Endothelial Progenitor Cell Markers
- Stem Cells>>Hematopoietic Stem Cells (HSCs)>>Hematopoietic Stem Cell (HSC) Marker
- Stem Cells>>Neural Stem Cells (NSCs)>>Mesenchymal Stem Cell (MSC) Marker
- Cardiovascular>>Angiogenesis>>Growth Factor & Receptor>>Receptor Tyrosine Kinase (RTK)
- Cancer>>Signal Transduction>>Protein Phosphorylation>>Tyrosine Kinase>>Receptor Tyrosine Kinases
- Cancer>>Signal Transduction>>Receptor Tyrosine Kinases (RTKs)
- Cancer>>Signal Transduction>>Akt Pathway>>Receptor Tyrosine Kinases (RTKs) in the Akt Pathway
- Cancer>>Signal Transduction>>Jak/STAT Signaling>>Receptors in the Jak/STAT Pathway
- VEGF
- Cardiovascular>>Angiogenesis>>Growth Factor & Receptor>>Vascular Endothelial Growth Factor (VEGF) & Receptor>>VEGF Receptor
References
- Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52.
- Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36.
- Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5.
- Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.
Recombinant Antibody Production Service
High-throughput Recombinant Antibody Production
